Study Identifies Potential Challenges from Long-Term Psychedelic Use

New research has looked into the lasting challenges people face after using psychedelics such as LSD and psilocybin. The researchers’ motivation lay in the increasing interest in and use of psychedelics for therapeutic purposes as well as personal growth. Numerous studies have shown that psychedelics have the potential to treat conditions such as anxiety, depression and post-traumatic stress disorder. Despite the benefits, however, some individuals may experience challenges following a psychedelic experience.

For their research, the investigators used channels such as newsletters, social media, newspaper ads and email lists to recruit more than 600 adults who had experienced challenges that last more than a day after a psychedelic experience. Each participant was asked to provide information about their experiences, including the substance used, dosage and the environment in which the experience took place. They were also asked about the nature and duration of the issues they experienced.

The researchers found that the most commonly used substances were psilocybin, LSD, ayahuasca, marijuana, MDMA, DMT, ketamine, mescaline and salvia divinorum, in that order. With regard to setting, the drugs were commonly used in the presence of a partner, a group of friends or one friend, followed by a solo experience then in a group ceremony. The researchers classified these experiences as unguided and guided.

The researchers determined that emotional difficulties such as fear and anxiety were the most common issues, together with self-perception issues and a disempowered self. They also determined that most individuals experienced issues that lasted an average of one to three years.  Other issues included existential difficulties, which comprised about 42% of total reports while delusional beliefs made up 6%.

Some participants also reported social difficulties, with others finding it harder to communicate and some noting they developed social anxiety. The report also noted that 21% of those surveyed reported perceptual difficulties while 7% experienced visual disturbances/hallucinations.

In addition, 18% of the participants reported cognitive issues, with obsessive thoughts and confusion being the leading subthemes. Furthermore, some experienced behavioral difficulties that made it difficult to perform in school or their careers. Finally, 5% of participants also admitted to experiencing symptoms that were similar to a psychotic episode.

Jules Evans, the author of the study, noted that she was surprised to learn how long some of these issues lasted.

The study’s findings were reported in the “PLOS One” journal.

Other researchers involved include Oliver C. Robinson, Ed Prideaux, Eirini Ketzitzidou Argyri, Rosalind McAlpine, Shayam Suseelan, Katrina Michelle, Ashleigh Murphy-Beiner and David Luke.

The possibility of long-term challenges arising from chronic psychedelic use makes a strong case for restricting the use of psychedelics to medical settings. Entities such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are working to take their psychedelic drug candidates through the FDA clinical-development process so that safe medicines are available to patients.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

PsychedelicNewsWire is powered by IBN


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050